Evolus (EOLS) Convertible Debt (2020)

Evolus' (EOLS) quarterly Convertible Debt came in at $40.5 million in Q4 2020, up 0.75% on a QoQ basis from $40.2 million in Q3 2020.

Evolus (EOLS) Convertible Debt (2020) Analysis & Trends

Evolus (EOLS) has 1 years of Convertible Debt data on file, last reported at $40.5 million in Q4 2020.

Quarterly Convertible Debt changed N/A year-over-year to $40.5 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $40.5 million (changed N/A YoY) and the FY2020 annual result came in at $40.5 million, changed N/A from the prior year.
Convertible Debt rose to $40.5 million in Q4 2020, from $40.2 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $40.5 million in Q4 2020 to a low of $40.2 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.34 Bn	43.38 Bn	-
2	Teva Pharmaceutical Industries	43.87 Bn	40.22 Bn	2.15 Bn
3	Zoetis	32.46 Bn	30.78 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.62 Bn	22.82 Bn	5.10 Bn
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn
6	Viatris	18.97 Bn	18.08 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.94 Bn	11.41 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.15 Bn	9.98 Bn	-
10	Evolus	553.80 Mn	508.63 Mn	57.18 Mn

Download Data

Date	Value
Dec 31, 2020	40.51 Mn
Sep 30, 2020	40.20 Mn